Growth hormone does not straightforwardly “cause” cancer, but it is not biologically innocent either. The GH-IGF-1 axis, the hormonal cascade that growth hormone triggers, promotes cell division and suppresses programmed cell death, both of which are relevant to tumor development. Yet decades of data on people receiving prescription growth hormone show no consistent increase in new cancers, and some analyses even suggest a reduced risk in GH-deficient adults who go on replacement therapy. The picture gets more interesting at the extremes: people whose bodies overproduce growth hormone face elevated cancer rates for certain tumors, while people born unable to respond to it appear almost entirely protected from malignancy.
How Growth Hormone Feeds Into Cancer Biology
Growth hormone itself does not act directly on most tissues the way, say, estrogen acts on breast cells. Instead, GH travels to the liver and other organs and stimulates production of insulin-like growth factor 1, or IGF-1. It is mainly IGF-1 that drives cell growth throughout the body. The GH-IGF-1 axis promotes cell proliferation and inhibits apoptosis, the orderly self-destruction cells are supposed to undergo when they are damaged or no longer needed.1Frontiers in Cell and Developmental Biology. Dual Characters of GH-IGF1 Signaling Pathways in Radiotherapy and Post-radiotherapy Repair of Cancers Those two properties, more growth and less cleanup, are exactly what a developing tumor wants.
Beyond that systemic role, researchers have found that some tumors produce their own growth hormone locally, creating an autocrine loop where the cancer essentially feeds itself. This local GH signaling appears to involve the same intracellular pathways that drive many cancers.2PubMed. Role of the growth hormone-IGF-1 axis in cancer The hormone can also reshape the microenvironment around a tumor, encouraging new blood vessel formation and helping cancer cells resist therapy.3PubMed Central. Growth hormone in the tumor microenvironment So at the molecular level, the concern is legitimate. The question is whether these laboratory mechanisms translate into real-world cancer risk when growth hormone levels change inside a human body.
What Happens When the Body Makes Too Much
The clearest natural experiment is acromegaly, a condition in which a benign pituitary tumor pumps out excess growth hormone for years or decades. People with acromegaly have chronically elevated IGF-1 levels, and their cancer risk is measurably higher than the general population’s. A 2023 meta-analysis found that thyroid cancer risk in acromegaly patients was about seven times higher than expected, while colorectal and anal cancer risk was roughly double.4PLOS ONE. Risk of cancer in acromegaly patients: An updated meta-analysis and systematic review An earlier clinical series found thyroid cancer in about one in ten acromegaly patients, making it by far the most common malignancy in that group.5PubMed. Increased thyroid cancer risk in acromegaly
These numbers sound alarming, but context matters. Acromegaly involves years of GH and IGF-1 levels far above anything a prescription dose produces. And even within this high-risk group, the findings have prompted debate about screening. Current guidelines do not recommend routine thyroid cancer screening for acromegaly patients beyond what the general population receives, partly because many of the thyroid cancers detected are small, slow-growing papillary tumors that may never become life-threatening.6Frontiers in Endocrinology. Acromegaly and Colorectal Neoplasm: An Update Colorectal screening, on the other hand, is widely recommended at earlier and more frequent intervals for acromegaly patients because the polyp and cancer risk there is more clinically meaningful.
What Happens When the Body Cannot Respond to GH at All
If excess GH raises cancer risk, you might expect the absence of GH signaling to lower it. That prediction turns out to be dramatically correct. People with Laron syndrome, a genetic condition in which the growth hormone receptor does not work, have extremely low IGF-1 levels throughout life. In a cohort of 230 Laron syndrome patients tracked over decades, not a single one developed cancer, even though some had been treated with IGF-1 and two had received GH injections. By contrast, their first-degree relatives, who have normal GH signaling, had cancer rates in line with the general population.7Endocrine-Related Cancer. Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome
A broader survey that included patients with other forms of congenital GH or IGF-1 deficiency found a similar pattern. Among 230 Laron syndrome patients and 116 patients with congenital isolated GH deficiency, cancer was essentially absent. Even in groups with partial defects in GH signaling, cancer occurred at very low rates.8European Journal of Endocrinology. Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies Genomic analyses of Laron syndrome patients have identified specific anti-cancer pathways that are upregulated in their cells, suggesting that lifelong low IGF-1 activates molecular safeguards against tumor development.9PubMed Central. Genome-Wide Profiling of Laron Syndrome Patients Identifies Novel Cancer Protection Pathways
The Laron syndrome story is one of the most striking findings in endocrine oncology. It does not prove that taking growth hormone causes cancer, but it does demonstrate that the GH-IGF-1 axis is deeply involved in whether cancer develops in the first place.
Growth Hormone Therapy in Children
Tens of thousands of children worldwide receive prescription GH for conditions ranging from GH deficiency to Turner syndrome to being born small for gestational age. Given the biological plausibility of a cancer link, these patients have been followed in large registries for decades. The evidence so far is reassuring.
A Swedish population-based study compared children who received GH treatment with matched controls drawn from the general population and found no increased risk of malignant tumors. The hazard ratio for malignancy was 0.91, meaning GH-treated children actually had slightly fewer cancers than controls, though the difference was not statistically meaningful.10Frontiers in Endocrinology. Long-term risk of neoplastic events after childhood growth hormone treatment: a population-based cohort study in Sweden The large European SAGhE cohort, which followed patients treated in childhood across multiple countries, found a similar picture: in children treated for isolated growth failure, overall cancer risk was not elevated, and no specific cancer type showed a significant increase.11The Journal of Clinical Endocrinology & Metabolism. Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study
A combined analysis of multiple international registries reinforced these findings, reporting no evidence of increased risk for new malignancies, leukemia, or non-leukemic tumors in GH-treated children who lacked pre-existing risk factors such as prior radiation or a cancer predisposition syndrome.12PubMed. Long-term safety of growth hormone-A combined registry analysis The one consistent flag is that children who had already been treated for cancer, and especially those who had received cranial radiation, do show a higher rate of second neoplasms. Whether GH itself contributes to that risk or radiation is the primary driver is discussed below.
GH Replacement in Adults With GH Deficiency
Adults who develop GH deficiency, often after pituitary surgery or radiation, are commonly prescribed replacement therapy to improve body composition, bone density, and quality of life. For these patients the cancer data is, if anything, encouraging. A meta-analysis found that GH replacement was associated with about a 30 percent lower risk of cancer compared to GH-deficient adults who were not treated.13PubMed Central. Growth hormone replacement therapy reduces risk of cancer in adult with growth hormone deficiency: A meta-analysis
The largest single-registry study, covering more than 15,000 GH-treated adults, reported an overall cancer incidence in line with the general population. The standardized incidence ratio for new cancers was 0.92, meaning treated patients developed cancer at a rate slightly below population expectations. Breast cancer risk was notably lower than expected. Patients with idiopathic or congenital GH deficiency who received replacement had an even lower cancer rate.14The Journal of Clinical Endocrinology & Metabolism. Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients These findings do not mean GH replacement protects against cancer. GH-deficient adults who go onto treatment may differ from the general population in many ways, including closer medical monitoring. But the data firmly argue against the idea that replacement-dose GH is a meaningful cancer trigger in this group.
A Harder Question: GH After Childhood Cancer
Many childhood cancer survivors, especially those treated with brain radiation, develop GH deficiency as a consequence of their treatment. These children and young adults need GH for normal growth and metabolic health, but prescribing a growth-promoting hormone to someone who already had cancer raises understandable anxiety. The evidence here is more nuanced than in other patient groups.
A major study from the Childhood Cancer Survivor Study found that GH therapy did not increase the risk of the original cancer coming back. The relative risk of disease recurrence in GH-treated survivors was 0.83, which was not statistically different from untreated survivors. GH use was also not associated with an increased risk of death.15The Journal of Clinical Endocrinology & Metabolism. Risk of Disease Recurrence and Second Neoplasms in Survivors of Childhood Cancer Treated with Growth Hormone: A Report from the Childhood Cancer Survivor Study However, GH-treated survivors did show a higher rate of second new tumors, all solid, primarily in survivors of acute leukemia. The authors urged caution in interpreting this finding because the absolute number of events was small.
A consensus statement from endocrinologists reviewing the full body of evidence concluded that the primary driver of secondary neoplasm risk in this population is prior radiation therapy, not GH replacement. Some studies have found an association between GH and secondary tumors, while others have not, and the inconsistency points toward confounding by radiation history.16European Journal of Endocrinology. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement The increased rate of meningiomas sometimes seen in GH-treated cancer survivors is also likely related to cranial irradiation rather than to GH itself.17PubMed Central. Growth Hormone Deficiency and Treatment in Childhood Cancer Survivors For clinicians, the practical takeaway is that GH can be prescribed to cancer survivors who need it, with careful long-term monitoring.
IGF-1 Levels and Cancer Risk in Healthy People
Separate from any medical therapy, researchers have spent decades asking whether people whose bodies naturally produce higher levels of IGF-1 face greater cancer risk. The answer, drawn from large population studies, is a modest but consistent yes for certain cancer types.
Data from more than 300,000 participants in the UK Biobank showed that people in the top fifth of circulating IGF-1 had roughly 20 to 25 percent higher risk of breast, prostate, and colorectal cancer compared with those in the bottom fifth.18PubMed Central. Circulating Insulin-Like Growth Factor-1 and Risk of Total and Site-specific Cancers: Cohort Study Analyses from the UK Biobank For prostate cancer specifically, a collaborative analysis pooling twenty prospective studies and using genetic techniques to distinguish cause from correlation found that higher IGF-1 was associated with increased risk of both overall and aggressive prostate cancer.19International Journal of Epidemiology. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis
For breast cancer, a pooled analysis of seventeen prospective studies found that women in the highest fifth of IGF-1 concentration had about 28 percent greater odds of breast cancer than women in the lowest fifth, with the association present in both premenopausal and postmenopausal women.20PubMed Central. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies For colorectal cancer, the association is weaker. A large European cohort study combined with a meta-analysis of prior data found a relatively modest link between IGF-1 and colorectal cancer risk overall.21PubMed. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies
These population-level associations do not mean that higher-IGF-1 individuals are destined to develop cancer. The absolute risk differences are small, and IGF-1 is only one of many factors influencing cancer development. But they do reinforce the biological plausibility of the GH-IGF-1 pathway as a contributor to cancer risk across the normal range of human hormonal variation, not just at the extremes of acromegaly or Laron syndrome.
Can You Lower Your IGF-1 Through Diet?
Given that higher circulating IGF-1 is associated with modestly increased cancer risk, a natural question is whether lifestyle changes can shift IGF-1 levels meaningfully. The answer is yes, to a degree, though the practical impact on cancer risk is still uncertain.
In rodent studies, calorie restriction, intermittent fasting, and fasting-mimicking diets have been shown to extend lifespan and reduce cancer incidence, and at least part of those benefits appears to be mediated through reduced GH-IGF-1 signaling.22Endocrine-Related Cancer. Nutrition, GH/IGF-1 signaling, and cancer In humans, IGF-1 levels respond to both total calorie intake and protein intake. Short-term fasting and the early phase of ketogenic diets can lower IGF-1, though levels often stabilize after several weeks if protein intake remains adequate.23Oncogenesis. Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer
What has not been established is whether deliberately lowering your IGF-1 through fasting or dietary changes translates into a measurable reduction in cancer risk over a human lifetime. The animal data is strong, but rodent metabolism and lifespan are different enough from ours that direct translation is risky. For now, the connection between diet, IGF-1, and cancer is a promising area of research rather than a proven intervention strategy.
Off-Label Use and Doping
Outside the clinic, growth hormone is used by athletes seeking performance enhancement and by people pursuing anti-aging effects. These uses involve doses and durations that go far beyond therapeutic replacement, and the cancer concern is more acute here. Preclinical evidence and the epidemiological experience with acromegaly both suggest that sustained supraphysiological GH/IGF-1 levels can promote cancer development and progression, and the doses used in doping may push levels higher than even therapeutic settings.24Pharmacological Research. Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?
This is an area where firm conclusions are hard to reach because people using GH illicitly do not enroll in registries or submit to long-term follow-up. But the theoretical risk is clear: if years of high IGF-1 in acromegaly raise cancer rates, then deliberately maintaining high IGF-1 through injections should carry a similar or greater risk. Anyone using GH outside of a medical prescription is effectively running a self-experiment with no safety monitoring.
Height, Cell Number, and Cancer
One indirect piece of evidence linking GH to cancer comes from an unexpected direction: height. Taller people face a modestly higher lifetime risk of cancer than shorter people, and GH is a major determinant of adult height. The leading explanation is straightforward: taller people have more cells, and more cells means more opportunities for the kind of random mutations that initiate cancer. A mathematical model of this relationship found that cancer risk does scale with estimated cell number in humans.25PubMed Central. Size matters: height, cell number and a person’s risk of cancer
Interestingly, this pattern does not hold across species. Elephants do not get more cancer than mice, despite having vastly more cells, a puzzle known as Peto’s paradox. Larger species appear to have evolved additional cancer suppression mechanisms. Within our own species, though, the GH-driven variation in body size does seem to carry a measurable cancer correlate. This does not mean being tall is dangerous in any practical sense; the increase is small and dwarfed by factors like smoking, obesity, and family history. But it adds another thread to the web connecting GH signaling to malignancy.
Blocking the GH-IGF-1 Axis as Cancer Therapy
If GH and IGF-1 promote tumor growth, blocking them should, in theory, slow tumors down. Researchers have explored this idea using pegvisomant, a drug already approved for treating acromegaly that works by blocking the growth hormone receptor. Early clinical pharmacology work showed that pegvisomant successfully reduced circulating IGF-1 and IGF-2 levels, and the investigators argued this provided grounds for testing the drug against tumors that depend on GH or IGF signaling, such as breast and colorectal cancers.26Clinical Cancer Research. Clinical Pharmacodynamic Effects of the Growth Hormone Receptor Antagonist Pegvisomant: Implications for Cancer Therapy
Preclinical experiments in animal models have further supported the concept, showing that blocking GH receptor signaling can slow tumor progression.27PubMed Central. Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications As a cancer treatment strategy, though, GH receptor blockade remains experimental. No large-scale clinical trials have demonstrated that pegvisomant improves cancer outcomes in humans, and the drug carries its own side effects. Still, the fact that researchers are actively exploring this axis as a therapeutic target underscores how seriously the GH-cancer connection is taken at the molecular level, even as the epidemiological data on GH therapy itself remains broadly reassuring.